Viroxime

We are open as normal during COVID-19 pandemic. Order online, same day shipping out from North Carolina, USA

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 528096

CAS#: 63198-97-0

Description: Viroxime is an antiviral Agent.


Price and Availability

Size Price Shipping out time Quantity
Inquire bulk and customized quantity

Pricing updated 2020-08-10. Prices are subject to change without notice.

Viroxime is not in stock, may be available through custom synthesis. For cost-effective reason, minimum 1 gram order is requested. The product will be characterized by NMR, HPLC and MS analysis. Purity (HPLC) is usually >98%. CoA, QC data, MSDS will be provided when product is successfully made. The estimated lead time is 2-3 months. Please send email to sales@medkoo.com to inquire quote.


Chemical Structure

img

Theoretical Analysis

MedKoo Cat#: 528096
Name: Viroxime
CAS#: 63198-97-0
Chemical Formula: C17H18N4O3S
Exact Mass: 358.11
Molecular Weight: 358.416
Elemental Analysis: C, 56.97; H, 5.06; N, 15.63; O, 13.39; S, 8.94


Synonym: Viroxime

IUPAC/Chemical Name: 1H-Benzimidazol-2-amine, 6-((hydroxyimino)phenylmethyl)-1-((1-methylethyl)sulfonyl)-

InChi Key: IWKXBHQELWQLHF-CAPFRKAQSA-N

InChi Code: InChI=1S/C17H18N4O3S/c1-11(2)25(23,24)21-15-10-13(8-9-14(15)19-17(21)18)16(20-22)12-6-4-3-5-7-12/h3-11,22H,1-2H3,(H2,18,19)/b20-16+

SMILES Code: NC1=NC2=CC=C(/C(C3=CC=CC=C3)=N/O)C=C2N1S(=O)(C(C)C)=O


Technical Data

Appearance:
Solid powder

Purity:
>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility:
Soluble in DMSO

Shelf Life:
>3 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code:
2934.99.03.00


References

1: Delang L, Harak C, Benkheil M, Khan H, Leyssen P, Andrews M, Lohmann V, Neyts J. PI4KIII inhibitor enviroxime impedes the replication of the hepatitis C virus by inhibiting PI3 kinases. J Antimicrob Chemother. 2018 Sep 14. doi: 10.1093/jac/dky327. [Epub ahead of print] PubMed PMID: 30219827.

2: Smee DF, Evans WJ, Nicolaou KC, Tarbet EB, Day CW. Susceptibilities of enterovirus D68, enterovirus 71, and rhinovirus 87 strains to various antiviral compounds. Antiviral Res. 2016 Jul;131:61-5. doi: 10.1016/j.antiviral.2016.04.003. Epub 2016 Apr 7. PubMed PMID: 27063860; PubMed Central PMCID: PMC5100981.

3: Han X, Sun N, Wu H, Guo D, Tien P, Dong C, Wu S, Zhou HB. Identification and Structure-Activity Relationships of Diarylhydrazides as Novel Potent and Selective Human Enterovirus Inhibitors. J Med Chem. 2016 Mar 10;59(5):2139-50. doi: 10.1021/acs.jmedchem.5b01803. Epub 2016 Feb 25. PubMed PMID: 26885567.

4: Sun L, Meijer A, Froeyen M, Zhang L, Thibaut HJ, Baggen J, George S, Vernachio J, van Kuppeveld FJ, Leyssen P, Hilgenfeld R, Neyts J, Delang L. Antiviral Activity of Broad-Spectrum and Enterovirus-Specific Inhibitors against Clinical Isolates of Enterovirus D68. Antimicrob Agents Chemother. 2015 Dec;59(12):7782-5. doi: 10.1128/AAC.01375-15. Epub 2015 Sep 14. PubMed PMID: 26369972; PubMed Central PMCID: PMC4649165.

5: Gao Q, Yuan S, Zhang C, Wang Y, Wang Y, He G, Zhang S, Altmeyer R, Zou G. Discovery of itraconazole with broad-spectrum in vitro antienterovirus activity that targets nonstructural protein 3A. Antimicrob Agents Chemother. 2015 May;59(5):2654-65. doi: 10.1128/AAC.05108-14. Epub 2015 Feb 17. PubMed PMID: 25691649; PubMed Central PMCID: PMC4394834.

6: Tijsma A, Franco D, Tucker S, Hilgenfeld R, Froeyen M, Leyssen P, Neyts J. The capsid binder Vapendavir and the novel protease inhibitor SG85 inhibit enterovirus 71 replication. Antimicrob Agents Chemother. 2014 Nov;58(11):6990-2. doi: 10.1128/AAC.03328-14. Epub 2014 Sep 8. PubMed PMID: 25199773; PubMed Central PMCID: PMC4249361.

7: Ford Siltz LA, Viktorova EG, Zhang B, Kouiavskaia D, Dragunsky E, Chumakov K, Isaacs L, Belov GA. New small-molecule inhibitors effectively blocking picornavirus replication. J Virol. 2014 Oct;88(19):11091-107. doi: 10.1128/JVI.01877-14. Epub 2014 Jul 9. PubMed PMID: 25008939; PubMed Central PMCID: PMC4178779.

8: Osiceanu AM, Murao LE, Kollanur D, Swinnen J, De Vleeschauwer AR, Lefebvre DJ, De Clercq K, Neyts J, Goris N. In vitro surrogate models to aid in the development of antivirals for the containment of foot-and-mouth disease outbreaks. Antiviral Res. 2014 May;105:59-63. doi: 10.1016/j.antiviral.2014.02.009. Epub 2014 Feb 25. PubMed PMID: 24583031.

9: Hausch S, Shurin JB, Matthews B. Variation in Body Shape across Species and Populations in a Radiation of Diaptomid Copepods. PLoS One. 2013 Jun 27;8(6):e68272. doi: 10.1371/journal.pone.0068272. Print 2013. PubMed PMID: 23826384; PubMed Central PMCID: PMC3694880.

10: Spickler C, Lippens J, Laberge MK, Desmeules S, Bellavance É, Garneau M, Guo T, Hucke O, Leyssen P, Neyts J, Vaillancourt FH, Décor A, O'Meara J, Franti M, Gauthier A. Phosphatidylinositol 4-kinase III beta is essential for replication of human rhinovirus and its inhibition causes a lethal phenotype in vivo. Antimicrob Agents Chemother. 2013 Jul;57(7):3358-68. doi: 10.1128/AAC.00303-13. Epub 2013 May 6. PubMed PMID: 23650168; PubMed Central PMCID: PMC3697394.

11: Debing Y, Kaplan GG, Neyts J, Jochmans D. Rapid and convenient assays to assess potential inhibitory activity on in vitro hepatitis A replication. Antiviral Res. 2013 May;98(2):325-31. doi: 10.1016/j.antiviral.2013.03.016. Epub 2013 Mar 23. PubMed PMID: 23528258.

12: Arita M, Kojima H, Nagano T, Okabe T, Wakita T, Shimizu H. Oxysterol-binding protein family I is the target of minor enviroxime-like compounds. J Virol. 2013 Apr;87(8):4252-60. doi: 10.1128/JVI.03546-12. Epub 2013 Jan 30. PubMed PMID: 23365445; PubMed Central PMCID: PMC3624399.

13: Arita M. [Exploration for anti-enterovirus compounds and analysis on the mechanism of its inhibitory effect on virus infection]. Uirusu. 2013;63(1):93-102. Review. Japanese. PubMed PMID: 24769585.

14: van der Schaar HM, van der Linden L, Lanke KH, Strating JR, Pürstinger G, de Vries E, de Haan CA, Neyts J, van Kuppeveld FJ. Coxsackievirus mutants that can bypass host factor PI4KIIIβ and the need for high levels of PI4P lipids for replication. Cell Res. 2012 Nov;22(11):1576-92. doi: 10.1038/cr.2012.129. Epub 2012 Sep 4. PubMed PMID: 22945356; PubMed Central PMCID: PMC3494396.

15: Aguado L, Canela MD, Thibaut HJ, Priego EM, Camarasa MJ, Leyssen P, Neyts J, Pérez-Pérez MJ. Efficient synthesis and anti-enteroviral activity of 9-arylpurines. Eur J Med Chem. 2012 Mar;49:279-88. doi: 10.1016/j.ejmech.2012.01.022. Epub 2012 Jan 17. PubMed PMID: 22305341.

16: Saha N, Jyrwa LM, Das M, Biswas K. Influence of increased environmental water salinity on gluconeogenesis in the air-breathing walking catfish, Clarias batrachus. Fish Physiol Biochem. 2011 Sep;37(3):681-92. doi: 10.1007/s10695-011-9468-1. Epub 2011 Feb 15. PubMed PMID: 21327497.

17: Arita M, Kojima H, Nagano T, Okabe T, Wakita T, Shimizu H. Phosphatidylinositol 4-kinase III beta is a target of enviroxime-like compounds for antipoliovirus activity. J Virol. 2011 Mar;85(5):2364-72. doi: 10.1128/JVI.02249-10. Epub 2010 Dec 22. PubMed PMID: 21177810; PubMed Central PMCID: PMC3067798.

18: Arita M, Takebe Y, Wakita T, Shimizu H. A bifunctional anti-enterovirus compound that inhibits replication and the early stage of enterovirus 71 infection. J Gen Virol. 2010 Nov;91(Pt 11):2734-44. doi: 10.1099/vir.0.023374-0. Epub 2010 Jul 21. PubMed PMID: 20660150.

19: Vanek A, Grygar T, Chrastný V, Tejnecký V, Drahota P, Komárek M. Assessment of the BCR sequential extraction procedure for thallium fractionation using synthetic mineral mixtures. J Hazard Mater. 2010 Apr 15;176(1-3):913-8. doi: 10.1016/j.jhazmat.2009.11.123. Epub 2009 Nov 27. PubMed PMID: 20022174.

20: Arita M, Wakita T, Shimizu H. Cellular kinase inhibitors that suppress enterovirus replication have a conserved target in viral protein 3A similar to that of enviroxime. J Gen Virol. 2009 Aug;90(Pt 8):1869-79. doi: 10.1099/vir.0.012096-0. Epub 2009 May 13. PubMed PMID: 19439558.